Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill Magnificent Seven ETF (MAGS) vs GeneDx Holdings Corp (WGS) Price & Performance

Roundhill Magnificent Seven ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Roundhill Magnificent Seven ETF vs GeneDx Holdings Corp — how do they compare? Roundhill Magnificent Seven ETF trades at $67.12, while GeneDx Holdings Corp trades at $60.64 (market cap $1.80B). The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

MAGSWGS
Sector
Sector/ThematicTechnology
52-Week High
$70.94$167.51
52-Week Low
$55.39$34.51
Market Cap
$1.80B
Enterprise Value
$1.80B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill Magnificent Seven ETF

MAGS, the Roundhill Magnificent Seven ETF, trades at $66.93, showing minimal daily movement with a neutral technical signal. It holds an equal-weight basket of seven mega-cap tech stocks, benefiting from AI-driven market trends but facing concentration risks. Recent news highlights AI spending shifts and broadening market gains beyond chipmakers.

The ETF's outlook hinges on AI adoption and hyperscaler performance, with potential from compressed valuations, but risks include overconcentration and high expectations. Institutional interest remains strong, though analyst views are mixed amid sector rotation.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.

Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.

Returns comparison

Trailing returns across standard periods

About Roundhill Magnificent Seven ETF

MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.

Read more on MAGS

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS